This Small-Cap Biotech Stock Is Onto Something Big
I recently had the pleasure of chatting with Flexion Therapeutics (NASDAQ: FLXN) CEO Mike Clayman about the company's plans for Zilretta, a newly approved medicine treating osteoarthritis of the knee. The company is in the midst of launching Zilretta, and if all goes well, it could eventually displace the use of corticosteroid shots in millions of patients. Is now a good time to buy Flexion Therapeutics shares? Read on to learn more about this company's opportunity.
Initially, doctors recommend over-the-counter pain medicines for patients who suffer from pain caused by osteoarthritis of the knee. However, when those medicines fail, doctors prescribe opioid pain medications and corticosteroid or hyaluronic acid injections.
Image source: Getty Images.
Source: Fool.com
